Dual bronchodilation in copd: Lung function and patient-reported outcomes – a review

International Journal of COPD

Volumn 12, Issue , 2017, Pages 141-168

  Price, David ^a,b   Østrem, Anders ^c   Thomas, Mike ^d   Welte, Tobias ^e  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

^b OBSERVATIONAL AND PRAGMATIC RESEARCH INSTITUTE   (Singapore)

^c Gransdalen Legesenter   (Norway)

^d UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^e HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Chronic obstructive pulmonary disease; Combination therapy; Dyspnea; Forced expiratory volume; Health status; Spirometry

Indexed keywords

ACLIDINIUM BROMIDE; ACLIDINIUM BROMIDE PLUS FORMOTEROL FUMARATE; FORMOTEROL; GLYCOPYRRONIUM; GLYCOPYRRONIUM BROMIDE PLUS INDACATEROL; INDACATEROL; OLODATEROL; OLODATEROL PLUS TIOTROPIUM BROMIDE; PLACEBO; TIOTROPIUM BROMIDE; UMECLIDINIUM; UMECLIDINIUM PLUS VILANTEROL; VILANTEROL; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; DRUG COMBINATION; MUSCARINIC RECEPTOR BLOCKING AGENT;

ARTICLE; ATRIAL FIBRILLATION; BRONCHODILATATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMBINATION CHEMOTHERAPY; DISEASE EXACERBATION; DRUG FORMULATION; DRUG SAFETY; DRUG TOLERABILITY; DUAL BRONCHODILATION; FIXED DOSE COMBINATION; FORCED EXPIRATORY VOLUME; HEALTH STATUS; HEART ATRIUM FLUTTER; HUMAN; LUNG FUNCTION; MONOTHERAPY; OUTCOME ASSESSMENT; PATIENT REPORTED OUTCOME; PATIENT SELECTION; PHASE 3 CLINICAL TRIAL (TOPIC); PNEUMONIA; POST HOC ANALYSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); SPIROMETRY; ST. GEORGE RESPIRATORY QUESTIONNAIRE; STUDY DESIGN; SYMPTOM; SYSTEMATIC REVIEW; TACHYCARDIA; TREATMENT DURATION; TREATMENT OUTCOME; XEROSTOMIA; CLINICAL TRIAL (TOPIC); CONVALESCENCE; DISEASE COURSE; DRUG COMBINATION; DRUG EFFECTS; INHALATIONAL DRUG ADMINISTRATION; LEAST SQUARE ANALYSIS; LUNG; METHODOLOGY; ODDS RATIO; PATHOPHYSIOLOGY; PATIENT-REPORTED OUTCOME; PROCEDURES; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

ADMINISTRATION, INHALATION; ADRENERGIC BETA-2 RECEPTOR AGONISTS; CLINICAL TRIALS AS TOPIC; DISEASE PROGRESSION; DRUG COMBINATIONS; FORCED EXPIRATORY VOLUME; HEALTH STATUS; HUMANS; LEAST-SQUARES ANALYSIS; LUNG; MUSCARINIC ANTAGONISTS; ODDS RATIO; PATIENT REPORTED OUTCOME MEASURES; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RECOVERY OF FUNCTION; RESEARCH DESIGN; TREATMENT OUTCOME;

EID: 85009471591     PISSN: 11769106     EISSN: 11782005     Source Type: Journal    
DOI: 10.2147/COPD.S116719     Document Type: Article

References (63)

1. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global Strategy for the Diagnosis, Management, and Prevention of COPD. Bethesda (MD): GOLD; 2016. Available from: http://goldcopd.org/global-strategy-diagnosis-management-prevention-copd-2016/. Accessed October 23, 2015.
2. Bateman ED, Ferguson GT, Barnes N, et al. Dual bronchodilation with QVA149 versus single bronchodilator therapy: the SHINE study. Eur Respir J. 2013;42(6):1484–1494.
3. Cazzola M, Molimard M. The scientific rationale for combining long-acting β2-agonists and muscarinic antagonists in COPD. Pulm Pharmacol Ther. 2010;23(4):257–267.
4. van Noord JA, Aumann JL, Janssens E, et al. Effects of tiotropium with and without formoterol on airflow obstruction and resting hyperinflation in patients with COPD. Chest. 2006;129(3):509–517.
5. Berton DC, Reis M, Siqueira AC, et al. Effects of tiotropium and formoterol on dynamic hyperinflation and exercise endurance in COPD. Respir Med. 2010;104(9):1288–1296.
6. Tashkin DP, Pearle J, Iezzoni D, Varghese ST. Formoterol and tiotropium compared with tiotropium alone for treatment of COPD. COPD. 2009;6(1):17–25.
7. Vogelmeier C, Kardos P, Harari S, Gans SJ, Stenglein S, Thirlwell J. Formoterol mono-and combination therapy with tiotropium in patients with COPD: a 6-month study. Respir Med. 2008;102(11):1511–1520.
8. Wang J, Jin D, Zuo P, Wang T, Xu Y, Xiong W. Comparison of tiotropium plus formoterol to tiotropium alone in stable chronic obstructive pulmonary disease: a meta-analysis. Respirology. 2011;16(2):350–358.
9. Tashkin DP, Donohue JF, Mahler DA, et al. Effects of arformoterol twice daily, tiotropium once daily, and their combination in patients with COPD. Respir Med. 2009;103(4):516–524.
10. Tashkin DP, Littner M, Andrews CP, TomLinson L, Rinehart M, Denis-Mize K. Concomitant treatment with nebulized formoterol and tiotropium in subjects with COPD: a placebo-controlled trial. Respir Med. 2008;102(4):479–487.
11. Hanania NA, Boota A, Kerwin E, TomLinson L, Denis-Mize K. Efficacy and safety of nebulized formoterol as add-on therapy in COPD patients receiving maintenance tiotropium bromide: results from a 6-week, randomized, placebo-controlled, clinical trial. Drugs. 2009;69(9):1205–1216.
12. van Noord JA, Aumann JL, Janssens E, et al. Combining tiotropium and salmeterol in COPD: effects on airflow obstruction and symptoms. Respir Med. 2010;104(7):995–1004.
13. Jones PW, Agusti AG. Outcomes and markers in the assessment of chronic obstructive pulmonary disease. Eur Respir J. 2006;27(4):822–832.
14. Jones PW, Beeh KM, Chapman KR, Decramer M, Mahler DA, Wedzicha JA. Minimal clinically important differences in pharmacological trials. Am J Respir Crit Care Med. 2014;189(3): 250–255.
15. Aisanov Z, Bai C, Bauerle O, et al. Primary care physician perceptions on the diagnosis and management of chronic obstructive pulmonary disease in diverse regions of the world. Int J Chron Obstruct Pulmon Dis. 2012;7:271–282.
16. Jones PW, Donohue JF, Nedelman J, Pascoe S, Pinault G, Lassen C. Correlating changes in lung function with patient outcomes in chronic obstructive pulmonary disease: a pooled analysis. Respir Res. 2011;12:161.
17. Jones PW. Health status measurement in chronic obstructive pulmonary disease. Thorax. 2001;56(11):880–887.
18. Westwood M, Bourbeau J, Jones PW, Cerulli A, Capkun-Niggli G, Worthy G. Relationship between FEV1 change and patient-reported outcomes in randomised trials of inhaled bronchodilators for stable COPD: a systematic review. Respir Res. 2011;12:40.
19. Haruna A, Oga T, Muro S, et al. Relationship between peripheral airway function and patient-reported outcomes in COPD: a cross-sectional study. BMC Pulm Med. 2010;10:10.
20. Watson L, Schouten JP, Löfdahl CG, Pride NB, Laitinen LA, Postma DS. Predictors of COPD symptoms: does the sex of the patient matter? Eur Respir J. 2006;28(2):311–318.
21. Donohue JF, Jones P, Bartels C, et al. Relationship between change in trough FEV1 and COPD patient outcomes: pooled analysis of 23 clinical trials in patients with COPD. Eur Respir J. 2015;46 Suppl 59: PA1013.
22. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6(7):e1000097.
23. Decramer M, Anzueto A, Kerwin E, et al. Efficacy and safety of umeclidinium plus vilanterol versus tiotropium, vilanterol, or umeclidinium monotherapies over 24 weeks in patients with chronic obstructive pulmonary disease: results from two multicentre, blinded, randomised controlled trials. Lancet Respir Med. 2014;2(6):472–486.
24. Zhong N, Wang C, Zhou X, et al. LANTERN: a randomized study of QVA149 versus salmeterol/fluticasone combination in patients with COPD. Int J Chron Obstruct Pulmon Dis. 2015;10:1015–1026.
25. Buhl R, Gessner C, Schuermann W, et al. Efficacy and safety of once-daily QVA149 compared with the free combination of once-daily tiotropium plus twice-daily formoterol in patients with moderate-to severe COPD (QUANTIFY): a randomised, non-inferiority study. Thorax. 2015;70(4):311–319.
26. Wedzicha JA, Banerji D, Chapman KR, et al. Indacaterol-glycopyrronium versus salmeterol-fluticasone for COPD. N Engl J Med. 2016;374(23):2222–2234.
27. Donohue JF, Worsley S, Zhu CQ, Hardaker L, Church A. Improvements in lung function with umeclidinium/vilanterol versus fluticasone propionate/salmeterol in patients with moderate-to-severe COPD and infrequent exacerbations. Respir Med. 2015;109(7):870–881.
28. Singh D, Jones PW, Bateman ED, et al. Efficacy and safety of aclidinium bromide/formoterol fumarate fixed-dose combinations compared with individual components and placebo in patients with COPD (ACLIFORM-COPD): a multicentre, randomised study. BMC Pulm Med. 2014;14:178.
29. D’Urzo AD, Rennard SI, Kerwin EM, Mergel V, Leslbaum AR, Caracta CF. Efficacy and safety of fixed-dose combinations of aclidinium bromide/formoterol fumarate: the 24-week, randomized, placebo-controlled AUGMENT COPD study. Respir Res. 2014;15:123.
30. Buhl R, Maltais F, Abrahams R, et al. Tiotropium and olodaterol fixed-dose combination versus mono-components in COPD (GOLD 2–4). Eur Respir J. 2015;45(4):969–979.
31. Beeh KM, Westerman J, Kirsten AM, et al. The 24-h lung-function profile of once-daily tiotropium and olodaterol fixed-dose combination in chronic obstructive pulmonary disease. Pulm Pharmacol Ther. 2015;32:53–59.
32. Maleki-Yazdi MR, Kaelin T, Richard N, Zvarich M, Church A. Efficacy and safety of umeclidinium/vilanterol 62.5/25 mcg and tiotropium 18 mcg in chronic obstructive pulmonary disease: Results of a 24-week, randomized, controlled trial. Respir Med. 2014;108(12): 1752–1760.
33. Maltais F, Singh S, Donald AC, et al. Effects of a combination of umeclidinium/vilanterol on exercise endurance in patients with chronic obstructive pulmonary disease: two randomized, double-blind clinical trials. Ther Adv Respir Dis. 2014;8(6):169–181.
34. O’Donnell D, Casaburi R, De Sousa D, et al. Effects of 6 weeks’ treatment with once-daily tiotropium and olodaterol fixed-dose combination on inspiratory capacity and exercise endurance in patients with COPD: the MORACTO studies. Am J Respir Crit Care Med. 2015;191(1):A3972.
35. Beeh KM, Korn S, Beier J, et al. Effect of QVA149 on lung volumes and exercise tolerance in COPD patients: the BRIGHT study. Respir Med. 2014;108(4):584–592.
36. Dahl R, Chapman KR, Rudolf M, et al. Safety and efficacy of dual bronchodilation with QVA149 in COPD patients: the ENLIGHTEN study. Respir Med. 2013;107(10):1558–1567.
37. Dahl R, Jadayel D, Alagappan VK, Chen H, Banerji D. Efficacy and safety of QVA149 compared to the concurrent administration of its monocomponents indacaterol and glycopyrronium: the BEACON study. Int J Chron Obstruct Pulmon Dis. 2013;8:501–508.
38. Mahler DA, Decramer M, D’Urzo A, et al. Dual bronchodilation with QVA149 reduces patient-reported dyspnoea in COPD: BLAZE study. Eur Respir J. 2014;43(6):1599–1609.
39. Vogelmeier CF, Bateman ED, Pallante J, et al. Efficacy and safety of once-daily QVA149 compared with twice-daily salmeterol-fluticasone in patients with chronic obstructive pulmonary disease (ILLUMINATE): a randomised, double-blind, parallel group study. Lancet Respir Med. 2013;1(1):51–60.
40. Wedzicha JA, Decramer M, Ficker JH, et al. Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, double-blind, parallel-group study. Lancet Respir Med. 2013;1(3):199–209.
41. Donohue JF, Maleki-Yazdi MR, Kilbride S, Mehta R, Kalberg C, Church A. Efficacy and safety of once-daily umeclidinium/vilanterol 62.5/25 mg in COPD. Respir Med. 2013;107(10):1538–1546.
42. Donohue JF, Singh D, Munzu C, Kilbride S, Church A. Magnitude of umeclidinium/vilanterol lung function effect depends on monotherapy responses: results from two randomised controlled trials. Respir Med. 2016;112:65–74.
43. Singh D, Worsley S, Zhu CQ, Hardaker L, Church A. Umeclidinium/vilanterol versus fluticasone propionate/salmeterol in COPD: a randomised trial. BMC Pulm Med. 2015;15:91.
44. Donohue JF, Niewoehner D, Brooks J, O’Dell D, Church A. Safety and tolerability of once-daily umeclidinium/vilanterol 125/25 mcg and umeclidinium 125 mcg in patients with chronic obstructive pulmonary disease: results from a 52-week, randomized, double-blind, placebo-controlled study. Respir Res. 2014;15:78.
45. Maltais F, Iturra JB, Kirsten A, et al. Effects of 12 weeks of once-daily tiotropium and olodaterol fixed-dose combination on exercise endurance in patients with COPD. Eur Respir J. 2014;44 Suppl 58:P283.
46. Donohue JF, Soong W, Wu X, Shrestha P, Lei A. Long-term safety of aclidinium bromide/formoterol fumarate fixed-dose combination: results of a randomized 1-year trial in patients with COPD. Respir Med. 2016;116:41–48.
47. Vogelmeier C, Paggiaro PL, Dorca J, et al. Efficacy and safety of aclidinium/formoterol versus salmeterol/fluticasone: a phase 3 COPD study. Eur Respir J. 2016;48(4):1030–1039.
48. Reisner C, Rose E, Strom S. Fixed combination of glycopyrrolate and formoterol MDI (GFF-MDI) demonstrates superior inspiratory capacity (IC) compared to tiotropium DPI (Tio) following 7 days dosing, in a randomized, double-blind, placebo-controlled phase 2B study in patients with COPD. Eur Respir J. 2011;38 Suppl 55:P879.
49. Reisner C, Rennard S, Fogarty C, et al. Pearl Therapeutics’ combination LAMA/LABA MDI (GFF-MDI, PT003) provides a significant benefit on home peak expiratory flow rate (PEFR) and reduces the need for rescue albuterol use compared to its components administered alone, Spiriva Handihaler, and Foradil Aerolizer in a randomized, double-blind, placebo-controlled phase 2B study in patients with COPD. Poster presented at: American Thoracic Society (ATS) International Conference; May 18–23, 2012; San Francisco, CA.
50. Reisner C, Gotfried M, Denenberg MB, et al. Low doses of Pearl Therapeutics’ LAMA/LABA combination MDI (GFF MDI, PT003) provide superior bronchodilation compared to components and to open-label Spiriva HandiHaler in a randomized, double-blind, placebo-controlled Phase IIB study in patients with COPD. Poster presented at: American Thoracic Society (ATS) International Conference; May 17–22, 2013; Philadelphia, PA.
51. Chapman KR, Bateman ED, Olsson P, Chen H, Banerji D, Fogel R. A significant proportion of patients with COPD show marked improvements in lung function with QVA149 (high responders): a post-hoc analysis of the SHINE study. Chronic Obstr Pulm Dis. 2015;2(2):159.
52. Bateman ED, Vogelmeier C, Chen H, Banerji D. Comparison of COPD exacerbations with once-daily QVA149 versus twice-daily salmeterol/fluticasone combination: the ILLUMINATE study. Chest. 2014;145(3):409A.
53. Jones PW. St. George’s Respiratory Questionnaire: MCID. COPD. 2005;2(1):75–79.
54. Wedzicha JA, Dahl R, Buhl R, et al. Pooled safety analysis of the fixed-dose combination of indacaterol and glycopyrronium (QVA149), its monocomponents, and tiotropium versus placebo in COPD patients. Respir Med. 2014;108(10):1498–1507.
55. Ferguson G, Barnes N, Mehta R, D’Andrea P, Chen H, Banerji D. Cardio-and cerebro-vascular safety profile of QVA149 in patients with COPD: a pooled analysis. Am J Respir Crit Care Med. 2013;187(1):A1488.
56. Van de Maele B, Fabbri LM, Martin C, Horton R, Dolker M, Overend T. Cardiovascular safety of QVA149, a combination of indacaterol and NVA237, in COPD patients. COPD. 2010;7(6):418–427.
57. US Food and Drug Administration. NDA 203-975: umeclidinium and vilanterol inhalation powder for the long-term, once-daily maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD). 2013. Available from: http://www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/drugs/pulmonary-allergydrugsadvisorycommittee/ucm367411.pdf. Accessed October 23, 2015.
58. Naccarelli G, Finkle J, Chopra B, Brooks J, Harris S, Church A. Cardiovascular safety of umeclidinium/vilanterol in COPD: results from eight randomized clinical trials. Poster presented at: American Thoracic Society (ATS) International Conference; May 16–21, 2014; San Diego, CA.
59. Manoharan A, Short PM, Anderson WJ, Lipworth BJ. Impact of long-acting bronchodilator therapy on mortality in COPD: a real-life retrospective cohort study. Thorax. 2013;68 (Suppl 3):A179–A180.
60. Di Marco F, Milic-Emili J, Boveri B, et al. Effect of inhaled bronchodilators on inspiratory capacity and dyspnoea at rest in COPD. Eur Respir J. 2003;21(1):86–94.
61. Roche N, Reddel HK, Agusti A, et al. Integrating real-life studies in the global therapeutic research framework. Lancet Respir Med. 2013;1(10):e29–e30.
62. Asai K, Minakata Y, Hirata K, et al. QVA149 once-daily is safe and well tolerated and improves lung function and health status in Japanese patients with COPD: the ARISE study. Eur Respir J. 2013;42 Suppl 57:694s.
63. D’Urzo A, Rennard S, Kerwin E, et al. One-year efficacy of aclidinium/formoterol fixed-dose combination in COPD patients: the AUGMENT COPD study. Poster presented at: European Respiratory Society (ERS) International Congress; September 6–10, 2014; Munich.